Abstract:Objective: To assess rates of traversing barriers to care to access optimal clinical outcomes in people with migraine internationally. Background: People in need of medical care for migraine should consult a health care professional knowledgeable in migraine management, obtain an accurate diagnosis, and receive an individualized treatment plan, which includes scientific society guideline-recommended treatments where appropriate. Methods: The Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study was a cross-sectional, web-based survey conducted from July 2021 through March 2022 in Canada, France, Germany, Japan, the United Kingdom, and the United States (US). Respondents who met modified International Classification of Headache Disorders, 3rd edition, criteria for migraine and had Migraine Disability Assessment Scale (MIDAS) scores of ≥ 6 (i.e., mild, moderate, or severe disability) were deemed to need medical care and were included in this analysis. Minimally effective treatment required that participants were currently consulting a health care professional for headache (barrier 1), reported an accurate diagnosis (barrier 2), and reported use of minimally appropriate pharmacologic treatment (barrier 3; based on American Headache Society 2021 Consensus Statement recommendations). Proportions of respondents who successfully traversed each barrier were calculated, and chi-square tests were used to assess overall difference among countries. Results: Among 14,492 respondents with migraine, 8,330 had MIDAS scores of ≥ 6, were deemed in need of medical care, and were included in this analysis. Current headache consultation was reported by 35.1% (2926/8330) of respondents. Compared with the US, consultation rates and diagnosis rates were statistically significantly lower in all other countries except France where they were statistically significantly higher. Total appropriate treatment rates were also statistically significantly lower in all other countries compared with the US except France, which did not differ from the US. All 3 barriers were traversed by only 11.5% (955/8330) of respondents, with differences among countries (P < 0.001). Conclusions: Of people with migraine in need of medical care for migraine, less than 15% traverse all 3 barriers to care. Although rates of consultation, diagnosis, and treatment differed among countries, improvements are needed in all countries studied to reduce the global burden of migraine. Trial registration: NA.

Health equity, care access and quality in headache – part 1

Hallmarks of primary headache: part 1 – migraine

Migraine: epidemiology and systems of care

Bridging the gaps of headache care for underserved populations: Current status of the headache field in Latin America

A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health?

Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain

Migraine - a borderland disease to epilepsy: near it but not of it

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study

Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society

Disparities in the Representation of Sex, Race and Ethnicity in Tension-Type Headache Clinical Trials

Learning the full impact of migraine through patient voices: A qualitative study

European headache federation consensus on the definition of resistant and refractory migraine

Living with migraine: A meta-synthesis of qualitative studies

Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study

Understanding Data and Opportunities Focused on Value: A Single-Center Experience in Headache Care

Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey

High-frequency episodic migraine: Time for its recognition as a migraine subtype?

Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel

Acute migraine in the Emergency Department: extending European principles of management

A Discrete-Choice Experiment Assessing the Patient Preferences and Real-World Experiences of Patients with Migraine in Japan